Ipsen los­es le­gal ap­peal over whether block­buster can­cer treat­ment is a drug or bi­o­log­ic

The phar­ma com­pa­ny Ipsen has lost the lat­est round of its le­gal ef­fort to have its block­buster can­cer prod­uct So­mat­u­line De­pot clas­si­fied as a bi­o­log­ic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER